PEPG Lawsuits

PEPG Investors Have Opportunity to Lead PepGen Inc. Securities Fraud Lawsuit with the Schall Law Firm

Published August 07, 2025 at 08:59 AM

LOS ANGELES, Aug. 7, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against PepGen Inc. ("PepGen" or "the Company") (NASDAQ: PEPG) for violations of §§10(b) and 20(a) of the Securities Exchange Act of...

Related Questions

What is the estimated exposure or liability for PepGen if the class action proceeds to trial or settlement? How does this lawsuit compare to similar securities‑fraud cases in the biotech/medical‑device sector in terms of outcomes and settlements? Could the lawsuit trigger any credit rating downgrades or covenant breaches for PepGen’s existing debt? How might the lawsuit affect analyst coverage, target price revisions, or institutional ownership of PepGen? Could the lawsuit result in a leadership or board change at PepGen? What is the likelihood that the case will be settled early versus going to a jury trial? What impact could this litigation have on PepGen's ability to raise capital or pursue the $30 M of financing it recently announced? Are there any insider trades or insider sales that have increased since the filing of the lawsuit? What are the potential impacts on PepGen’s pipeline and product development timelines? How might this lawsuit affect PepGen’s relationships with key customers, partners, or suppliers? How will the lawsuit settlement or potential damages affect PepGen's short‑term stock volatility? What is the timeline for the litigation and any upcoming court filings or deadlines?